Provided by Tiger Trade Technology Pte. Ltd.

Capricor Therapeutics

9.47
+0.900010.50%
Post-market: 9.46-0.0101-0.11%19:59 EDT
Volume:20.57M
Turnover:208.71M
Market Cap:550.58M
PE:-3.84
High:10.72
Open:10.03
Low:9.40
Close:8.57
52wk High:40.37
52wk Low:2.96
Shares:58.14M
Float Shares:42.60M
Volume Ratio:8.40
T/O Rate:48.28%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.4659
EPS(LYR):-2.2601
ROE:-73.70%
ROA:-33.63%
PB:2.24
PE(LYR):-4.19

Loading ...

Capricor Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 13

Capricor Therapeutics Q1 Loss Widens

MT Newswires Live
·
May 13

Capricor Q1 FY26 net loss widens to $33.9 million; revenue remains no revenue

Reuters
·
May 13

Capricor Therapeutics options imply 9.4% move in share price post-earnings

TIPRANKS
·
May 13

Capricor Therapeutics Q1 EPS $(0.59) Misses $(0.50) Estimate

Benzinga Earnings
·
May 13

Capricor Therapeutics Inc - No Revenue Recognized for Q1 2026 or Q1 2025

THOMSON REUTERS
·
May 13

Capricor Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

THOMSON REUTERS
·
May 13

Capricor Therapeutics: Available Cash, Cash Equivalents, Marketable Securities Sufficient to Cover Expenses & Capital Requirements Through Q4 2027

THOMSON REUTERS
·
May 13

Analysts Offer Insights on Healthcare Companies: ImageneBio (IMA) and Capricor Therapeutics (CAPR)

TIPRANKS
·
May 11

Capricor files suit against NS Pharma over Deramiocel distribution deal

TIPRANKS
·
May 09

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Capricor Therapeutics (CAPR), Enovis (ENOV) and Progyny (PGNY)

TIPRANKS
·
May 09

Capricor Therapeutics Says NS Pharma Delays Could Threaten Access To Duchenne Therapy

Benzinga
·
May 08

H.C. Wainwright Sticks to Its Buy Rating for Capricor Therapeutics (CAPR)

TIPRANKS
·
May 08

Capricor sues Nippon Shinyaku over US distribution rights for CAP-1002

Reuters
·
May 08

Capricor Therapeutics Inc - Alleges Ns Pharma Failed to Prepare for Deramiocel Launch and Breached Agreement - SEC Filing

THOMSON REUTERS
·
May 08

Capricor Therapeutics Inc - Files Lawsuit and Seeks Preliminary Injunction in New Jersey Court on May 7, 2026 - SEC Filing

THOMSON REUTERS
·
May 08

Earning Preview: Capricor Therapeutics this quarter’s revenue is expected to decrease by 100%, and institutional views are bullish

Earnings Agent
·
May 06

Capricor CFO Anthony Bergmann disposes of 25,000 shares worth $792,540

Reuters
·
May 05

Capricor EVP, General Counsel Karen Krasney disposes 25,000 shares for $792,548‬

Reuters
·
May 05

Capricor Therapeutics schedules first-quarter 2026 financial results conference call and webcast

Reuters
·
May 05